Last reviewed · How we verify
NCT07251660
Comparison of Early Postoperative Outcomes Between Minimally Invasive Valve Surgery Via Right Thoracotomy and Conventional Valve Surgery Via Sternotomy.
NA trial testing Minimally Invasive Valve Surgery in Heart Valve Diseases or Prosthesis in 32 participants. Not yet recruiting.
15 July 2026
Quick facts
| Lead sponsor | Chaudhry Pervaiz Elahi Institute of Cardiology |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 15 December 2025 |
| Primary completion | 15 July 2026 |
| Estimated completion | 15 August 2026 |
Drugs / interventions tested
- Minimally Invasive Valve Surgery
- Conventional Valve Surgery
Conditions studied
- Heart Valve Diseases or Prosthesis — all drugs for Heart Valve Diseases or Prosthesis →
- Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
- Aortic Valve Insufficiency — all drugs for Aortic Valve Insufficiency →
- Valvular Heart Disease Stenosis and Regurgitation (Diagnosis) — all drugs for Valvular Heart Disease Stenosis and Regurgitation (Diagnosis) →
Sponsor
Chaudhry Pervaiz Elahi Institute of Cardiology
Who can join
Eligibility, any sex, with Heart Valve Diseases or Prosthesis or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled trial aims to compare early postoperative outcomes between Minimally Invasive Valve Surgery (MIVS) via right thoracotomy and Conventional Valve Surgery via median sternotomy in patients undergoing elective, isolated mitral or aortic valve surgery. Minimally invasive techniques are believed to reduce postoperative pain, ventilation time, chest drain output, and wound complications, but evidence from Pakistan is limited. The study will enroll patients of all ages and genders who are scheduled for isolated valvular procedures at Chaudhary Pervaiz Elahi Institute of Cardiology (CPEIC), Multan. Participants will be randomly assigned to undergo either minimally invasive thoracotomy or conventional sternotomy. Primary outcomes include ventilation time, CPB duration, cross-clamp time, pain scores, and chest drain output. Secondary outcomes include wound healing (Day 7 and 30 days), return to routine activity, echocardiographic evaluation, transfusion requirements, and 30-day mortality. Findings from this study may provide evidence to guide the adoption of minimally invasive valvular surgery techniques in low-resource and developing settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07251660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chaudhry Pervaiz Elahi Institute of Cardiology trials
Trials by the same sponsor.
- NCT04700215 — Comparison of BiPAP and ٰIS in Reducing Post CABG Pulmonary Complications · NA · unknown
- NCT05218161 — Hemodynamic Effect of Dexmedetomidine Alone With Dexmedetomidine Plus Ketamine Combination in CABG · NA · unknown
- NCT05290324 — Propofol or Midazolam for Sedation and Early Extubation Following Coronary Artery Bypass Graft Surgery · NA · completed
- NCT05004545 — Compare Hemodynamic Parameters of Propofol and Sevoflurane During CPB Time in Undergoing CABG to Avoid Lactate Level · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07251660 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chaudhry Pervaiz Elahi Institute of Cardiology
- Last refreshed: 26 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07251660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing